Viking Therapeutics, Inc. (Nasdaq:VKTX), a pioneering clinical-stage biopharmaceutical company focused on developing innovative therapies for metabolic and endocrine disorders, is thrilled to announce the successful closing of a $24 million funding round. This significant investment will bolster the advancement of Viking鈥檚 promising research pipeline and enhance its ability to bring groundbreaking therapies to market. Currently, the company is making strides in clinical development with its lead candidate, a non-steroidal selective androgen receptor modulator (SARM), which is undergoing a Phase 2 trial aimed at enhancing recovery outcomes for patients following hip fracture surgery. Additionally, Viking is advancing its thyroid receptor beta (TRb) agonist platform, which is also in Phase 2 trials, targeting lipid disorders such as hypercholesterolemia and critical liver diseases, including non-alcoholic steatohepatitis (NASH). The funding will not only support these key therapeutic candidates but will also facilitate exploration into rare diseases like glycogen storage disease (GSD 1a) and X-linked adrenoleukodystrophy (X-ALD). With this new infusion of capital, Viking Therapeutics is poised to accelerate its research efforts, driving the development of first-in-class treatments that can significantly improve patient outcomes in areas of high unmet medical need. As always, we remain committed to scientific excellence and innovation, and we look forward to sharing future milestones with our stakeholders. For more information about our ongoing projects, please visit our website at http://www.vikingtherapeutics.com.
Announcing Viking Therapeutics' $24 Million Funding Round for Breakthrough Metabolic Disorder Therapies
Recently funded 路 $24.0MHealthcare
Get the full Viking Therapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
